-+ 0.00%
-+ 0.00%
-+ 0.00%

KYMERA THERAPEUTICS INC - KT-621 BROADEN2 PHASE 2B TRIAL TO SEVERE AD ONGOING, DATA EXPECTED BY MID-2027

Reuters·12/08/2025 12:00:02

Please log in to view news